Four randomised controlled trials were included, but the number of participants involved in these four trials was not reported in the review.
Quality: the quality scores ranged from 3 to 5 out of a maximum of 5. All the studies were graded 'B' (unclear) for adequacy of concealment.
Number of incontinent episodes per 24-hour period: oxybutynin was superior to tolterodine in decreasing the number of episodes (WMD 0.41, 95% CI: 0.04, 0.77).
Quantity of pad use per 24-hour period: only one study reported 24-hour pad use, with the tolterodine group using 1.1 pads less (p<0.0003).
Number of micturitions per 24-hour period: there was no significant difference between the treatments (WMD 0.00,; 95% CI: -0.38, 0.38).
Mean voided volume per micturition: oxybutynin was superior to tolterodine; the change in volume voided was -8.24 mL (95% CI: -14.11, -2.38).
Adverse events: fewer patients taking tolterodine had dry mouth (RR 0.54, 95% CI: 0.48, 0.61) and withdrew from the study because of side-effects (RR 0.63, 95% CI: 0.46, 0.88).
Urologic measurements: none of the included studies reported on urodynamic variables.
Quality of life: no data were reported.